References
Key articles
National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. March 2023 [internet publication].Full text
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer [internet publication].Full text
European Society for Medical Oncology. Oncogene-mediated metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Jan 2023 [internet publication].Full text
Hendriks L E, Kerr K, Menis J, et al. on behalf of the ESMO Guidelines Committee. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Jan 2023;34(4):358-76.Full text
Jaiyesimi IA, Leighl NB, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3. J Clin Oncol. 2024 Apr 10;42(11):e1-22.Full text Abstract
Jaiyesimi IA, Leighl NB, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2023.3. J Clin Oncol. 2024 Apr 10;42(11):e23-43.Full text Abstract
Reference articles
1. American Cancer Society. Key statistics for lung cancer. Jan 2024 [internet publication].Full text
2. WHO Classification of Tumours Editorial Board. Thoracic tumours: World Health Organization classification of tumours. 5th ed, vol 3. Lyon, France: International Agency for Research on Cancer; 2021.Full text
3. Ost DE, Yeung SC, Tanoue LT, et al. Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e121S-e141S.Full text Abstract
4. Wudel LJ, Nesbitt JC. Superior vena cava syndrome. Curr Treat Options Oncol. 2001 Feb;2(1):77-91. Abstract
5. Archie VC, Thomas CR Jr. Superior sulcus tumors: a mini-review. Oncologist. 2004 Sep 1;9(5):550-5.Full text Abstract
6. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.Full text Abstract
7. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: lung and bronchus cancer [internet publication].Full text
8. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.Full text Abstract
9. GBD 2019 Respiratory Tract Cancers Collaborators. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Respir Med. 2021 Sep;9(9):1030-49.Full text Abstract
10. Centers for Disease Control and Prevention. Burden of cigarette use in the US. May 2023 [internet publication].Full text
11. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e1S-e29S.Full text Abstract
12. Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene. 2002 Oct 7;21(45):6870-6. Abstract
13. Ngoc LTN, Park D, Lee YC. Human health impacts of residential radon exposure: updated systematic review and meta-analysis of case-control studies. Int J Environ Res Public Health. 2022 Dec 21;20(1):97.Full text Abstract
14. Darby S, Hill D, Deo H, et al. Residential radon and lung cancer--detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13 epidemiologic studies in Europe. Scand J Work Environ Health. 2006;32 (suppl 1):1-83.Full text Abstract
15. Curiel-García T, Rey-Brandariz J, Varela-Lema L, et al. Asbestos exposure and small cell lung cancer: systematic review and meta-analysis. J Occup Environ Hyg. 2023 Oct;20(10):427-38. Abstract
16. Nielsen LS, Bælum J, Rasmussen J, et al. Occupational asbestos exposure and lung cancer--a systematic review of the literature. Arch Environ Occup Health. 2014;69(4):191-206. Abstract
17. Raaschou-Neilsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol. 2013 Aug;14(9):813-22. Abstract
18. Zhang Y, Vaccarella S, Morgan E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023 Nov;24(11):1206-18. Abstract
19. Subramanian J, Morgensztern D, Goodgame B, et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol. 2010 Jan;5(1):23-8. Abstract
20. Franks TJ, Galvin JR. Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis. Arch Pathol Lab Med. 2010 Jan;134(1):49-54.Full text Abstract
21. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85. Abstract
22. Takahashi S, Tanaka N, Okimoto T, et al. Long term follow-up for small pure ground-glass nodules: implications of determining an optimum follow-up period and high-resolution CT findings to predict the growth of nodules. Jpn J Radiol. 2012 Apr;30(3):206-17. Abstract
23. Kim TJ, Park CM, Goo JM, et al. Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity? AJR Am J Roentgenol. 2012 Jan;198(1):83-8.Full text Abstract
24. Kim TJ, Goo JM, Lee KW, et al. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung Cancer. 2009 May;64(2):171-8. Abstract
25. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology. 2009 Jan;54(1):12-27. Abstract
26. Doll R, Hill D. Smoking and carcinoma of the lung; a preliminary report. BMJ. 1950 Sep 30;2(4682):739-48. Abstract
27. Levin ML, Goldstein H, Gerhardt PR. Cancer and tobacco smoking; a preliminary report. JAMA. 1950 May 27;143(4):336-8. Abstract
28. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of six hundred and eighty-four proved cases. JAMA. 1950 May 27;143(4):329-36. Abstract
29. Pérez-Ríos M, López-Medina DC, Guerra-Tort C, et al. Mortality attributable to environmental tobacco smoke exposure in Spain in 2020. [in spa]. Arch Bronconeumol. 2023 May;59(5):305-10.Full text Abstract
30. Hori M, Tanaka H, Wakai K, et al. Secondhand smoke exposure and risk of lung cancer in Japan: a systematic review and meta-analysis of epidemiologic studies. Jpn J Clin Oncol. 2016 Oct;46(10):942-51.Full text Abstract
31. Copas JB, Shi JQ. Reanalysis of epidemiological evidence on lung cancer and passive smoking. BMJ. 2000 Feb 12;320(7232):417-8.Full text Abstract
32. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009 Aug;34(2):380-6.Full text Abstract
33. Gonzalez J, Marín M, Sánchez-Salcedo P, et al. Lung cancer screening in patients with chronic obstructive pulmonary disease. Ann Transl Med. 2016 Apr;4(8):160.Full text Abstract
34. Zhang Z, Zhang X, Gao Y, et al. Risk factors for the development of lung cancer among never smokers: a systematic review. Cancer Epidemiol. 2022 Dec;81:102274.Full text Abstract
35. Park HY, Kang D, Shin SH, et al. Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study. Thorax. 2020 Jun;75(6):506-9.Full text Abstract
36. Powell HA, Iyen-Omofoman B, Baldwin DR, et al. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. J Thorac Oncol. 2013 Apr;8(4):e34-5. Abstract
37. Nitadori J, Inoue M, Iwasaki M, et al. Association between lung cancer incidence and family history of lung cancer: data from a large-scale population-based cohort study, the JPHC study. Chest 2006 Oct;130(4):968-75. Abstract
38. Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ. 2005 Jan 29;330(7485):223.Full text Abstract
39. World Health Organization. Radon and health. Jan 2023 [internet publication].Full text
40. Milner J, Shrubsole C, Das P, et al. Home energy efficiency and radon related risk of lung cancer: modelling study. BMJ. 2014 Jan 10;348:f7493.Full text Abstract
41. Leone FT, Evers-Casey S, Toll BA, et al. Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e61S-e77S.Full text Abstract
42. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.Full text Abstract
43. Cortés-Jofré M, Rueda JR, Asenjo-Lobos C, et al. Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev. 2020 Mar 4;3(3):CD002141.Full text Abstract
44. US Preventive Services Task Force; Mangione CM, Barry MJ, et al. Vitamin, mineral, and multivitamin supplementation to prevent cardiovascular disease and cancer: US Preventive Services Task Force recommendation statement. JAMA. 2022 Jun 21;327(23):2326-33.Full text Abstract
45. Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: diagnosis and management of lung cancer. 3rd ed. American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e455S-e497S.Full text Abstract
46. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med. 1989 May;149(5):1076-80. Abstract
47. Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022 Feb 10;40(5):492-516.Full text Abstract
48. American College of Radiology. ACR appropriateness criteria: noninvasive clinical staging of primary lung cancer. 2018 [internet publication].Full text
49. National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. March 2023 [internet publication].Full text
50. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e142S-e165S.Full text Abstract
51. Schwartz AM, Rezaei MK. Diagnostic surgical pathology in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e251S-e262S.Full text Abstract
52. Blum TG, Morgan RL, Durieux V, et al. European Respiratory Society guideline on various aspects of quality in lung cancer care. Eur Respir J. 2023 Feb;61(2):2103201.Full text Abstract
53. Kang HJ, Hwangbo B, Lee GK, et al. EBUS-centred versus EUS-centred mediastinal staging in lung cancer: a randomised controlled trial. Thorax. 2014 Mar;69(3):261-8. Abstract
54. National Institute for Health and Care Excellence. Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. February 2008 [internet publication].Full text
55. Adams K, Shah PL, Edmonds L, et al. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax. 2009 Sep;64(9):757-62. Abstract
56. Gu P, Zhao YZ, Jiang LY, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer. 2009 May;45(8):1389-96. Abstract
57. Varela-Lema L, Fernandez-Villar A, Ruano-Ravina A, et al. Effectiveness and safety of endobronchial ultrasound-transbronchial needle aspiration: a systematic review. Eur Respir J. 2009 May;33(5):1156-64. Abstract
58. Chen W, Gao X, Tian Q, et al. A comparison of autofluorescence bronchoscopy and white light bronchoscopy in detection of lung cancer and preneoplastic lesions: a meta-analysis. Lung Cancer. 2011 Aug;73(2):183-8. Abstract
59. Sun J, Garfield DH, Lam B, et al. The value of autofluorescence bronchoscopy combined with white light bronchoscopy compared with white light alone in the diagnosis of intraepithelial neoplasia and invasive lung cancer: a meta-analysis. J Thorac Oncol. 2011 Aug;6(8):1336-44. Abstract
60. Port J, Harrison S. Electromagnetic navigational bronchoscopy. Semin Intervent Radiol. 2013 Jun;30(2):128-32.Full text Abstract
61. Dubé JP, Azzi Z, Semionov A, et al. Imaging of post transthoracic needle biopsy complications. Can Assoc Radiol J. 2019 May;70(2):156-63.Full text Abstract
62. British Thoracic Society. BTS Pleural disease guideline 2010. August 2010 [internet publication]. [This guideline has been archived by the British Thoracic Society. The BTS website states that guidelines that are more than 5 years old are marked as archived because their recommendations have not been checked to confirm continued validity at the date of archival. A BMJ Best Practice expert adviser has confirmed that these guidelines still reflect current practice in the UK.]Full text
63. National Patient Safety Agency. Rapid response report: risks of chest drain insertion. May 2008. http://www.nrls.npsa.nhs.uk/ (last accessed 26 October 2017).Full text
64. Akram AR, Hartung TK. Intercostal chest drains: a wake-up call from the National Patient Safety Agency rapid response report. J R Coll Physicians Edinb. 2009;39:117-120.Full text
65. American College of Surgeons Committee on Trauma. Advanced trauma life support (ATLS) student course manual. 8th ed. Chicago, IL: American College of Surgeons; 2008.
66. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e211S-e250S.Full text Abstract
67. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer [internet publication].Full text
68. Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA. 2010 Nov 24;304(20):2245-52.Full text Abstract
69. Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015 Jun;47(6):545-59.Full text Abstract
70. Kumaran M, Benamore RE, Vaidhyanath R, et al. Ultrasound guided cytological aspiration of supraclavicular lymph nodes in patients with suspected lung cancer. Thorax. 2005 Mar;60(3):229-33. Abstract
71. Rodrigues M, Stark H, Rendl G, et al. Diagnostic performance of [18F] FDG PET-CT compared to bone scintigraphy for the detection of bone metastases in lung cancer patients. Q J Nucl Med Mol Imaging. 2016 Mar;60(1):62-8.Full text Abstract
72. European Society for Medical Oncology. Oncogene-mediated metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Jan 2023 [internet publication].Full text
73. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012 Mar 10;30(8):863-70.Full text Abstract
74. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011 Sep 10;29(26):3574-9.Full text Abstract
75. Cui G, Liu D, Li W, et al. A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer. Medicine (Baltimore). 2017 Apr;96(14):e6552. Abstract
76. Gautschi O, Milia J, Filleron T, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol. 2017 May 1;35(13):1403-10.Full text Abstract
77. Michels S, Scheel AH, Scheffler M, et al. Clinicopathological characteristics of RET rearranged lung cancer in European patients. J Thorac Oncol. 2016 Jan;11(1):122-7.Full text Abstract
78. Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018 Sept;13(9):1302-11.Full text Abstract
79. Hendriks L E, Kerr K, Menis J, et al. on behalf of the ESMO Guidelines Committee. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Jan 2023;34(4):358-76.Full text
80. Miller KL, Shafman TD, Marks LB. A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer. Semin Radiat Oncol. 2004 Oct;14(4):298-307. Abstract
81. Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e166S-e190S.Full text Abstract
82. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56(12):2015-38. Abstract
83. Beckles MA, Spiro SG, Colice GL, et al. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 2003 Jan;123(1 Suppl):97S-104S. Abstract
84. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5.Full text Abstract
85. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000 Feb;117(2):358-64. Abstract
86. Galluzzi S, Payne PM. Bronchial carcinoma: a statistical study of 741 necropsies with special reference to the distribution of blood-borne metastases. Br J Cancer. 1955 Dec;9(4):511-27. Abstract
87. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest. 1998 Dec;114(6):1535-7. Abstract
88. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 1999 Nov;213(2):530-6. Abstract
89. Toloza EM, Harpole L, Detterbeck F, et al. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 suppl):157S-166S. Abstract
90. Porcel JM, Pardina M, Bielsa S, et al. Derivation and validation of a CT scan scoring system for discriminating malignant from benign pleural effusions. Chest. 2015 Feb;147(2):513-9. Abstract
91. Savage PJ, Donovan WN, Dellinger RP. Sputum cytology in the management of patients with lung cancer. South Med J. 1984 Jul;77(7):840-2. Abstract
92. Pastis NJ Jr, Silvestri GA. Tissue procurement: bronchoscopic techniques. In: Pass HI, Carbone DP, Johnson DH, et al, eds. Lung cancer: principles and practice, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:358-71.
93. Micames CG, McCrory DC, Pavey DA, et al. Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: a systematic review and metaanalysis. Chest. 2007 Feb;131(2):539-48. Abstract
94. Rintoul RC, Glover MJ, Jackson C, et al. Cost effectiveness of endosonography versus surgical staging in potentially resectable lung cancer: a health economics analysis of the ASTER trial from a European perspective. Thorax. 2014 Jul;69(7):679-81. Abstract
95. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 Suppl):137S-146S. Abstract
96. Schmidt-Hansen M, Baldwin DR, Hasler E, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014 Nov 13;(11):CD009519.Full text Abstract
97. Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA. 2014 Sep 24;312(12):1227-36.Full text Abstract
98. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004 Jul 15;22(14):2942-53. Abstract
99. Ozkaya S, Bilgin S, Hamsici S, et al. The pulmonary radiologic findings of rheumatoid arthritis. Respir Med CME. 2011;4(4):187-92.Full text
100. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM classification of malignant tumours. 8th edition. Chichester: Wiley-Blackwell; 2016.
101. Amin MB, Edge S, Greene, F, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
102. Rami-Porta R, ed. IASLC Staging Manual in Thoracic Oncology. 2nd edition. North Fort Myers, FL: Editorial Rx Press; 2016.
103. Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017 Jan 1;151(1):193-203.Full text Abstract
104. Detterbeck FC. The eighth edition TNM stage classification for lung cancer: what does it mean on main street? J Thorac Cardiovasc Surg. 2018 Jan 1;155(1):356-9.Full text Abstract
105. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. Abstract
106. Bonney A, Malouf R, Marchal C, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev. 2022 Aug 3;8(8):CD013829.Full text Abstract
107. Aberle DR, Adams AM, Berg CD, et al; The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409.Full text Abstract
108. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020 Feb 6;382(6):503-13.Full text Abstract
109. US Preventive Services Task Force. Lung cancer: screening. March 2021 [internet publication].Full text
110. American College of Radiology. ACR appropriateness criteria®: lung cancer screening. 2022 [internet publication].Full text
111. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: lung cancer screening [internet publication].Full text
112. American Cancer Society. Lung cancer screening guidelines. Jan 2024 [internet publication].Full text
113. Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 Oct;16(10):1647-62.Full text Abstract
114. Postmus PE, Kerr KM, Oudkerk M, et al.; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1–21.Full text
115. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42.Full text Abstract
116. Moeller B, Balagamwala EH, Chen A, et al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018 Jul-Aug;8(4):245-50.Full text Abstract
117. Brunelli A, Charloux A, Bolliger CT, et al.; European Respiratory Society; European Society of Thoracic Surgeons Joint Task Force on Fitness For Radical Therapy. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg. 2009 Jul;36(1):181-4.Full text Abstract
118. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 Sep;60(3):615-22. Abstract
119. Kim D, Woo W, Shin JI, et al. The uncomfortable truth: open thoracotomy versus minimally invasive surgery in lung cancer: a systematic review and meta-analysis. Cancers (Basel). 2023 May 5;15(9):2630.Full text Abstract
120. Liu S, Li S, Tang Y, et al. Minimally invasive surgery vs. open thoracotomy for non-small-cell lung cancer with N2 disease: a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1152421.Full text Abstract
121. Pezzi CM, Mallin K, Mendez AS, et al. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg. 2014 Nov;148(5):2269-77.Full text Abstract
122. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e278S-e313S.Full text Abstract
123. Myrdal G, Gustafsson G, Lambe M, et al. Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardiothorac Surg. 2001 Oct;20(4):694-9.Full text Abstract
124. Powell HA, Tata LJ, Baldwin DR, et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. Thorax. 2013 Sep;68(9):826-34.Full text Abstract
125. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014 May 3;383(9928):1561-71.Full text Abstract
126. Felip E, Rosell R, Maestre JA, et al; Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010 Jul 1;28(19):3138-45. Abstract
127. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol. 2005 Jun 1;23(suppl 1):624.
128. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022 May 26;386(21):1973-85. Abstract
129. Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023 Aug 10;389(6):491-503.Full text Abstract
130. Ligibel JA, Bohlke K, Alfano CM. Exercise, diet, and weight management during cancer treatment: ASCO guideline summary and Q&A. JCO Oncol Pract. 2022 Jul 5;OP2200277.Full text Abstract
131. Granger C, Cavalheri V. Preoperative exercise training for people with non-small cell lung cancer. Cochrane Database Syst Rev. 2022 Sep 28;9(9):CD012020.Full text Abstract
132. Cavalheri V, Burtin C, Formico VR, et al. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database Syst Rev. 2019 Jun 17;6:CD009955.Full text Abstract
133. Gravier FE, Smondack P, Prieur G, et al. Effects of exercise training in people with non-small cell lung cancer before lung resection: a systematic review and meta-analysis. Thorax. 2022 May;77(5):486-96. Abstract
134. Arriagada R, Bergman B, Dunant A, et al; The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60.Full text Abstract
135. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. Abstract
136. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97.Full text Abstract
137. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. Abstract
138. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 1;28(1):29-34.Full text Abstract
139. Burdett S, Pignon JP, Tierney J, et al; Non-Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015 Mar 2;(3):CD011430.Full text Abstract
140. Pisters K, Kris MG, Gaspar LE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Apr 1;40(10):1127-29.Full text Abstract
141. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010 Apr 10;375(9722):1267-77.Full text Abstract
142. Bradbury P, Sivajohanathan D, Chan A, et al. Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017 May;18(3):259-73.e8. Abstract
144. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-57. Abstract
145. O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1274-86. Abstract
146. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020 Oct 29;383(18):1711-23.Full text Abstract
147. Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023 Apr 1;41(10):1830-40.Full text Abstract
148. Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-47.Full text Abstract
149. Singh N, Daly ME, Ismaila N, et al. Management of stage III non-small-cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Sep 20;41(27):4430-2.Full text Abstract
150. O'Reilly D, Botticella A, Barry S, et al. Treatment decisions for resectable non-small-cell lung cancer: balancing less with more? Am Soc Clin Oncol Educ Book. 2023 May;43:e389950.Full text Abstract
151. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998 Jul 25;352(9124):257-63. Abstract
152. Luchini C, Veronese N, Nottegar A, et al. Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. Virchows Arch. 2018 Jun;472(6):939-47. Abstract
153. Lester JF, Coles B, Macbeth FR. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD005221.Full text Abstract
154. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31. Abstract
155. Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019 Apr;20(4):494-503. Abstract
156. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006 Oct 20;24(30):4833-9. Abstract
157. Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1149-56. Abstract
158. Fintelmann FJ, Graur A, Oueidat K, et al. Ablation of stage I-II non-small cell lung cancer in patients with interstitial lung disease: a multicenter retrospective study. AJR Am J Roentgenol. 2024 Feb;222(2):e2330300.Full text Abstract
159. Wang J, Li B, Zhang L, et al. Safety and local efficacy of computed tomography-guided microwave ablation for treating early-stage non-small cell lung cancer adjacent to bronchovascular bundles. Eur Radiol. 2024 Jan;34(1):236-46.Full text Abstract
160. National Institute for Health and Care Excellence. Percutaneous radiofrequency ablation for primary or secondary lung cancers. December 2010 [internet publication].Full text
161. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e314S-e340S.Full text Abstract
162. Daly ME, Singh N, Ismaila N, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022 Apr 20;40(12):1356-84.Full text Abstract
163. Putora PM, Leskow P, McDonald F, et al. International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Res. 2020 Jan;6(1):00159-2019.Full text Abstract
164. Simone CB 2nd, Bradley J, Chen AB, et al. ASTRO radiation therapy summary of the ASCO guideline on management of stage III non-small cell lung cancer. Pract Radiat Oncol. 2023 May-Jun;13(3):195-202.Full text Abstract
165. Chen Y, Peng X, Zhou Y, et al. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis. World J Surg Oncol. 2018 Jan 16;16(1):8.Full text Abstract
166. Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012 Jun;93(6):1807-12.Full text Abstract
167. Thomas M, Rübe C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008 Jul;9(7):636-48.Full text Abstract
168. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692-9. Abstract
169. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC. Proc Am Soc Clin Oncol. 2003 Jan 1;22:621.
170. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007 Mar 21;99(6):442-50.Full text Abstract
171. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342-50.Full text Abstract
172. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919-29.Full text Abstract
173. National Institute for Health and Care Excellence. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. Jun 2022 [internet publication].Full text
174. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J Clin Oncol. 2018 Mar 20;36(9):911-9.Full text Abstract
175. Iyengar P, All S, Berry MF, et al. Treatment of oligometastatic non-small cell lung cancer: an ASTRO/ESTRO clinical practice guideline. Pract Radiat Oncol. 2023 Sep-Oct;13(5):393-412.Full text Abstract
176. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].Full text
177. Inoue A, Kobayashi K, Usui K,et al; North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009 Mar 20;27(9):1394-400.Full text Abstract
178. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(suppl 4):iv192-iv237.Full text Abstract
179. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Abstract
180. Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD010383.Full text Abstract
181. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-69. Abstract
182. Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Abstract
183. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-66. Abstract
184. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-25. Abstract
185. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50.Full text Abstract
186. Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Aug 28 [Epub ahead of print].Full text Abstract
187. Deng W, Wang K, Jiang Y, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022 Aug 19;12(8):e062036.Full text Abstract
188. Cappuzzo F, Ciuleanu T, Stelmakh L, et al; SATURN Investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. Abstract
189. Rosell R, Moran T, Queralt C, et al; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958-67.Full text Abstract
190. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021 Oct 20;39(30):3391-402.Full text Abstract
191. Jaiyesimi IA, Leighl NB, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3. J Clin Oncol. 2024 Apr 10;42(11):e1-22.Full text Abstract
192. Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020 Feb 10;38(5):488-95.Full text Abstract
193. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Abstract
194. Cameron LB, Hitchen N, Chandran E, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453.Full text Abstract
195. Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023 Apr;11(4):354-66. Abstract
196. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963-71.Full text Abstract
197. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-70.Full text Abstract
198. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-82.Full text Abstract
199. Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024 Jan 11;390(2):118-31.Full text Abstract
200. Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019 Dec;20(12):1691-701. Abstract
201. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93.Full text Abstract
202. Riely GJ, Smit EF, Ahn MJ, et al. Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer. J Clin Oncol. 2023 Jul 20;41(21):3700-11.Full text Abstract
203. Subbiah V, Gervais R, Riely G, et al. Efficacy of vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol. 2019 Jun 27;3:PO.18.00266.Full text Abstract
204. Wu YL, Zhang L, Kim DW, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018 Nov 1;36(31):3101-09.Full text Abstract
205. Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020 Sep 3;383(10):944-57.Full text Abstract
206. Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020 Sep 3;383(10):931-43.Full text Abstract
207. Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020 Jan;26(1):47-51. Abstract
208. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020 Aug 27;383(9):813-24.Full text Abstract
209. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 Jul;22(7):959-69. Abstract
210. Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016 Dec;17(12):1653-60. Abstract
211. Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy Ffrom the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023 Jan 10;41(2):385-94.Full text Abstract
212. Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023 Nov 16;389(20):1839-50.Full text Abstract
213. European Society for Medical Oncology. Pralsetinib: measures to minimise increased risk for tuberculosis. May 2023 [internet publication].Full text
214. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021 Jun 24;384(25):2371-81.Full text Abstract
215. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med. 2022 Jul 14;387(2):120-31.Full text Abstract
216. de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023 Mar 4;401(10378):733-46. Abstract
217. Dy GK, Govindan R, Velcheti V, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100. J Clin Oncol. 2023 Jun 20;41(18):3311-7.Full text Abstract
218. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022 Jan 20;386(3):241-51.Full text Abstract
219. Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021 Nov 9;375:n2363. Abstract
220. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021 Dec 20;39(36):4073-126. [Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315.]Full text Abstract
221. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.Full text Abstract
222. Beavers CJ, Rodgers JE, Bagnola AJ, et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation. 2022 Apr 12;145(15):e811-e38.Full text Abstract
223. Thuny F, Naidoo J, Neilan TG. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J. 2022 Nov 7;43(42):4458-68.Full text Abstract
224. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-33.Full text Abstract
225. Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021 Mar 20;39(9):1040-91.Full text Abstract
226. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-30. Abstract
227. Jassem J, de Marinis F, Giaccone G, et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC. J Thorac Oncol. 2021 Nov;16(11):1872-82. Abstract
228. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020 Oct 1;383(14):1328-39.Full text Abstract
229. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021 Feb 13;397(10274):592-604. Abstract
230. Jaiyesimi IA, Leighl NB, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2023.3. J Clin Oncol. 2024 Apr 10;42(11):e23-43.Full text Abstract
231. Ferrara R, Imbimbo M, Malouf R, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257.Full text Abstract
232. Kanabar SS, Tiwari A, Soran V, et al. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax. 2022 Dec;77(12):1163-74. Abstract
233. Socinski MA, Jotte RM, Cappuzzo F, et al. Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol. 2023 Apr 1;9(4):527-35.Full text Abstract
234. Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022 Nov;28(11):2374-80.Full text Abstract
235. de Castro G Jr, Kudaba I, Wu YL, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 study. J Clin Oncol. 2023 Apr 10;41(11):1986-91.Full text Abstract
236. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-31.Full text Abstract
237. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2022 Feb;17(2):289-308.Full text Abstract
238. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Abstract
239. Gandhi L, Rodríguez-Abreu D, Gadgeel S,et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-92. Abstract
240. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-51.Full text Abstract
241. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020 May 10;38(14):1505-17.Full text Abstract
242. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288-01.Full text Abstract
243. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019 May;7(5):387-401. Abstract
244. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. Abstract
245. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-37. Abstract
246. Johnson ML, Cho BC, Luft A, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol. 2023 Feb 20;41(6):1213-27.Full text Abstract
247. Gijtenbeek RG, de Jong K, Venmans BJ, et al. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Database Syst Rev. 2023 Jul 7;7(7):CD013382.Full text Abstract
248. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018 Oct 1;36(28):2872-8. Abstract
249. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.Full text Abstract
250. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51.Full text Abstract
251. Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014 Oct;15(11):1254-62. Abstract
252. Pilkington G, Boland A, Brown T, et al. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. 2015 Apr;70(4):359-67. Abstract
253. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct 24;374(9699):1432-40. Abstract
254. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Abstract
255. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.Full text Abstract
256. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123-35.Full text Abstract
257. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-33. Abstract
258. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. Abstract
259. Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021 Mar 1;39(7):723-33.Full text Abstract
260. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50. Abstract
261. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-65. Abstract
262. Reck M, Kaiser R, Mellemgaard A, et al; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb;15(2):143-55. Abstract
263. Cortot AB, Audigier-Valette C, Molinier O, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. Eur J Cancer. 2020 May;131:27-36. Abstract
264. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665-73. Abstract
265. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94.Full text Abstract
266. Asciak R, Bedawi EO, Bhatnagar R, et al. British Thoracic Society Clinical Statement on pleural procedures. Thorax. 2023 Jul;78(suppl 3):s43-s68.Full text Abstract
267. Nakitende D, Gottlieb M, Ruskis J, et al. Ultrasound for confirmation of thoracostomy tube placement by emergency medicine residents. Trauma (United Kingdom). 2015;19(1):35‐8.
268. Jenkins JA, Gharahbaghian L, Doniger SJ, et al. Sonographic identification of tube thoracostomy study (SITTS): confirmation of intrathoracic placement. West J Emerg Med. 2012 Sep;13(4):305-11.Full text Abstract
269. Ford DW, Koch KA, Ray DE, et al. Palliative and end-of-life care in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e498S-e512S.Full text Abstract
270. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020 Nov 1;38(31):3592-603.Full text Abstract
271. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018 Aug 20;36(24):2532-7.Full text Abstract
272. Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021 May 1;7(5):709-17. Abstract
273. He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021 Sep;9(9):1021-29. Abstract
274. Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021 Nov 1;7(11):1617-25.Full text Abstract
275. Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209-19. Abstract
276. Lu S, Dong X, Jian H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022 Sep 20;40(27):3162-71.Full text Abstract
277. ClinicalTrials.gov. Combination study with soluble LAG-3 fusion protein eftilagimod alpha (IMP321) and pembrolizumab in patients with previously untreated unresectable or metastatic NSCLC, or recurrent PD-X refractory NSCLC or with recurrent or metastatic HNSCC (TACTI-002). 2023 [internet publication].Full text
278. ClinicalTrials.gov. APL-101 study of subjects with NSCLC with c-met EXON 14 skip mutations and c-met dysregulation advanced solid tumors (SPARTA). 2024 [internet publication].Full text
279. Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022 Nov;10(11):1019-28.Full text Abstract
280. Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Sep;23(9):1167-79.Full text Abstract
281. Wang Z, Wu L, Li B, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01). J Clin Oncol. 2023 Jan 20;41(3):651-63.Full text Abstract
282. Shi Y, Chen J, Yang R, et al. Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC: interim analysis of a randomized, open-label, phase 3 study (INSPIRE). J Thorac Oncol. 2024 Jan 25;S1556-0864(24)00033-9.Full text Abstract
283. Zhong H, Sun S, Chen J, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 2024 May;12(5):355-65. Abstract
284. Powell H, Tata L, Baldwin DR, et al. Treatment decisions and survival for people with small cell lung cancer. Brit J Cancer. 2014 Feb 18;110(4):908-15. Abstract
285. Khakwani A, Rich AL, Powell HA, et al. Lung cancer survival In England: trends in non-small cell lung cancer survival over the duration of the National Lung Cancer Audit. Brit J Cancer. 2013 Oct 15;109(8):2058-65. Abstract
286. Oda M, Watanabe Y, Shimizu J, et al. Extent of mediastinal node metastasis in clinical stage I non-small-cell lung cancer: the role of systematic nodal dissection. Lung Cancer. 1998 Oct;22(1):23-30. Abstract
287. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016 Jan;11(1):39-51.Full text Abstract
288. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004 Nov 1;22(21):4341-50. Abstract
289. Miller KL, Shafman TD, Anscher MS, et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):64-9. Abstract
290. Colt HG, Murgu SD, Korst RJ, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e437S-e454S.Full text Abstract
291. Schneider BJ, Ismaila N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol. 2020 Mar 1;38(7):753-66.Full text Abstract
292. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010 Jan 21;340:b5569. Abstract
Use of this content is subject to our disclaimer